Drug Profile

Devimistat - Cornerstone Pharmaceuticals Inc

Alternative Names: 6,8-bis(benzylthio)octanoic-acid; Bylantra; CPI-613; ONO-7912

Latest Information Update: 01 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cornerstone Pharmaceuticals; Stony Brook University
Developer Case Comprehensive Cancer Center; Cornerstone Pharmaceuticals Inc; National Cancer Institute (USA); Ono Pharmaceutical; University of Michigan; Wake Forest University Health Sciences; Wake Forest University School of Medicine
Class Antineoplastics; Carboxylic acids; Coenzymes; Fatty acids; Small molecules; Sulfides
Mechanism of Action Ketoglutarate dehydrogenase complex inhibitors; Pyruvate dehydrogenase complex inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Myelodysplastic syndromes; Burkitt's lymphoma; Biliary cancer; Acute myeloid leukaemia; Soft tissue sarcoma; Pancreatic cancer; Peripheral T-cell lymphoma; T-cell lymphoma
New Molecular Entity Yes

Phase III Acute myeloid leukaemia; Pancreatic cancer
Phase II B-cell lymphoma; Burkitt's lymphoma; Small cell lung cancer; Solid tumours; T-cell lymphoma
Phase I/II Biliary cancer; Cancer; Clear cell sarcoma; Colorectal cancer
Phase I Hodgkin's disease
Discontinued Myelodysplastic syndromes

25 Apr 2025 Efficacy and adverse event data from phase II trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
25 Apr 2025 Pharmacodynamics data from preclinical studies in Triple negative breast cancer presented at the 116^th Annual Meeting of the American Association for Cancer Research (AACR-2025)
07 Dec 2024 Efficacy and adverse events data from phase-II trial in Burkitt Lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com